No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
0.5 mg budesonide effervescent tablet for orodispersible use |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 98 |
2 |
1 mg budesonide effervescent tablet for orodispersible use |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 98 |
3 |
1mg budesonide effervescent tablet for orodispersible use |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 98 |
4 |
2mg budesonide effervescent tablet for orodispersible use |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 98 |
5 |
5 mg montelukast |
Montelukast |
D00529, D08229 |
1件: CYSLTR1 |
2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction |
1件: 98 |
6 |
Ak002 |
- |
- |
- |
- |
1件: 98 |
7 |
Allergy immunotherapy (allergy shots) |
- |
- |
- |
- |
1件: 98 |
8 |
Apt-1011 |
- |
- |
- |
- |
1件: 98 |
9 |
Barium |
Barium |
- |
- |
- |
1件: 98 |
10 |
Beclomethasone dipropionate |
Beclomethasone dipropionate |
D00689, D07495 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
2件: 97, 98 |
11 |
Bethanechol |
Bethanechol |
D01000 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 |
11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
1件: 98 |
12 |
Budesonide |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
9件: 66, 93, 94, 95, 96, 97, 98, 228, 299 |
13 |
Budesonide 0.5mg orodispersible tablet twice daily |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 98 |
14 |
Budesonide 1mg orodispersible tablet twice daily |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 98 |
15 |
Budesonide [0.4mg/ml] viscous suspension |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 98 |
16 |
Budesonide oral suspension |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 98 |
17 |
Budesonide oral suspension [0.2 mg/ml] |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 98 |
18 |
Budesonide plus prevacid |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 98 |
19 |
Buet 0.5 mg |
- |
- |
- |
- |
1件: 98 |
20 |
Buet 1mg |
- |
- |
- |
- |
1件: 98 |
21 |
Buet 2mg |
- |
- |
- |
- |
1件: 98 |
22 |
Buu 0.4mg/ml |
- |
- |
- |
- |
1件: 98 |
23 |
Cromolyn |
Cromoglicic acid |
D00526, D07753 |
- |
- |
2件: 85, 98 |
24 |
Dexlansoprazole |
Dexlansoprazole |
D08903 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
1件: 98 |
25 |
Dupilumab |
Dupilumab |
D10354 |
1件: IL4R |
8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation |
1件: 98 |
26 |
Dupilumab (blinded) |
Dupilumab |
D10354 |
1件: IL4R |
8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation |
1件: 98 |
27 |
Dupilumab (open-label) |
Dupilumab |
D10354 |
1件: IL4R |
8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation |
1件: 98 |
28 |
Esomeprazole |
Esomeprazole |
D01984, D04056, D07917, D09339 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
6件: 6, 46, 86, 98, 298, 299 |
29 |
Eur-1100 |
- |
- |
- |
- |
1件: 98 |
30 |
Florence 30 µg/ml |
- |
- |
- |
- |
1件: 98 |
31 |
Florence 60 µg/ml |
- |
- |
- |
- |
1件: 98 |
32 |
Florence 90 µg/ml |
- |
- |
- |
- |
1件: 98 |
33 |
Flovent |
Fluticasone propionate |
D01708 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 98 |
34 |
Flovent (fluticasone propionate) |
Fluticasone propionate |
D01708 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 98 |
35 |
Fluticasone |
Fluticasone |
D07981 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
4件: 98, 228, 299, 306 |
36 |
Fluticasone mdi |
Fluticasone |
D07981 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 98 |
37 |
Fluticasone propionate |
Fluticasone propionate |
D01708 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
3件: 98, 228, 306 |
38 |
Honey |
Honey |
D06776 |
- |
- |
2件: 57, 98 |
39 |
Infliximab |
Infliximab |
D02598 |
1件: TNF |
61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
22件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 95, 96, 97, 98, 162, 164, 269, 271 |
40 |
Inhaled/swallowed budesonide |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 98 |
41 |
Intubated with propofol (ip) |
Propofol |
D00549 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
1件: 98 |
42 |
Intubated with sevoflurane (is) |
Sevoflurane |
D00547 |
- |
- |
1件: 98 |
43 |
Lansoprazole |
Lansoprazole |
D00355 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
6件: 63, 71, 98, 166, 222, 299 |
44 |
Losartan |
Losartan |
D00357, D08146 |
1件: AGTR1 |
14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
18件: 13, 17, 19, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 |
45 |
Losartan potassium |
Potassium |
D08403 |
- |
- |
4件: 98, 167, 179, 215 |
46 |
Mepolizumab |
Mepolizumab |
D04923 |
1件: IL5 |
13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation |
4件: 44, 45, 98, 162 |
47 |
Mepolizumab 100 mg |
Mepolizumab |
D04923 |
1件: IL5 |
13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation |
1件: 98 |
48 |
Mepolizumab 300 mg |
Mepolizumab |
D04923 |
1件: IL5 |
13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation |
1件: 98 |
49 |
Monitor |
Methamidophos |
- |
- |
- |
12件: 2, 11, 13, 19, 46, 49, 58, 70, 85, 98, 298, 300 |
50 |
Montelukast |
Montelukast |
D00529, D08229 |
1件: CYSLTR1 |
2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction |
5件: 13, 46, 85, 98, 228 |
51 |
Montelukast/ singulair |
Montelukast |
D00529, D08229 |
1件: CYSLTR1 |
2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction |
1件: 98 |
52 |
Nasonex |
Mometasone furoate |
D00690 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 98 |
53 |
Nitric oxide |
Nitric oxide |
D00074 |
- |
- |
7件: 46, 85, 86, 98, 251, 294, 299 |
54 |
Oc000459 |
- |
- |
- |
- |
1件: 98 |
55 |
Omalizumab |
Omalizumab |
D05251 |
1件: FCER1A |
4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway |
6件: 53, 65, 98, 162, 226, 299 |
56 |
Omeprazole |
Omeprazole |
D00455, D01207, D05259, D05261 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
15件: 6, 8, 13, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 |
57 |
Omeprazole 20mg bid |
Omeprazole |
D00455, D01207, D05259, D05261 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
1件: 98 |
58 |
Oral budesonide |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 98 |
59 |
Oral budesonide suspension (mb-9) |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 98 |
60 |
Oral budesonide suspension (obs) |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 98 |
61 |
Oral cromolyn sodium |
Cromoglicic acid |
D00526, D07753 |
- |
- |
1件: 98 |
62 |
Oral viscous budesonide |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 98 |
63 |
Oral viscous budesonide (ovb) |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 98 |
64 |
Potassium |
Potassium |
D08403 |
- |
- |
9件: 46, 66, 67, 98, 115, 167, 179, 215, 235 |
65 |
Propofol |
Propofol |
D00549 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ |
7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
8件: 6, 21, 22, 34, 46, 84, 98, 296 |
66 |
Qax576 |
- |
- |
- |
- |
4件: 51, 85, 96, 98 |
67 |
Reslizumab |
Reslizumab |
D08985 |
1件: IL5 |
13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation |
3件: 44, 45, 98 |
68 |
Rpc4046 |
- |
- |
- |
- |
1件: 98 |
69 |
Sb-240563 |
- |
- |
- |
- |
3件: 44, 45, 98 |
70 |
Sch55700 |
- |
- |
- |
- |
1件: 98 |
71 |
Sevoflurane |
Sevoflurane |
D00547 |
- |
- |
5件: 6, 21, 22, 98, 296 |
72 |
Sirolimus |
Sirolimus |
D00753 |
1件: MTOR |
43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
30件: 13, 17, 34, 35, 36, 46, 51, 60, 62, 63, 65, 66, 67, 85, 89, 96, 98, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331 |
73 |
Steroid and proton pump inhibitor therapy |
- |
- |
- |
- |
1件: 98 |
74 |
Sucralfate |
Sucralfate |
D00446 |
- |
- |
1件: 98 |
75 |
Swallowed fluticasone |
Fluticasone |
D07981 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 98 |
76 |
Technetium tc 99m |
Technetium tc-99m |
- |
- |
- |
1件: 98 |
77 |
Treat with lansoprazole 30 mg bid for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms |
Lansoprazole |
D00355 |
2件: ATP4A, ATP4B |
4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
1件: 98 |
78 |
Viaskin milk 500 mcg |
- |
- |
- |
- |
1件: 98 |
79 |
Viscous/swallowed budesonide |
Budesonide |
D00246 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 98 |
80 |
Vitamin d |
Vitamin d |
- |
- |
- |
18件: 13, 19, 41, 46, 49, 50, 68, 93, 95, 96, 98, 179, 222, 228, 235, 274, 298, 299 |
81 |
Vonoprazan |
Vonoprazan |
- |
- |
- |
2件: 63, 98 |
82 |
Wheat |
Wheat |
D06902 |
- |
- |
2件: 98, 266 |
83 |
Xanthan gum |
Xanthan gum |
D06333 |
- |
- |
1件: 98 |
84 |
Xylose |
Xylose |
D06346 |
- |
- |
1件: 98 |
85 |
Zofran - no intubation |
- |
- |
- |
- |
1件: 98 |